Case report

Coronavirus disease-19 (COVID-19) associated with acute necrotising pancreatitis (ANP)

Naren K Kumaran,* Biraj K Karmakar, Ormond M Taylor†

SUMMARY

Coronavirus is a severe infectious disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that leads to increased mortality worldwide. Multiple reports have been published citing that gastrointestinal symptoms are common in patients with COVID-19 infection. It has also been found that the ACE2 receptor of SARS-CoV-2 is expressed more in the pancreas than the lungs. Despite this, little attention has been paid to the extent and details of pancreatic injury caused by COVID-19. Lack of awareness regarding the COVID-19 status of patients presenting with pancreatitis may expose healthcare workers to SARS-CoV-2 while performing interventions to manage complications of pancreatitis such as necrosis. We report a case of COVID-19-induced acute necrotising pancreatitis in the absence of any known risk factors.

BACKGROUND

Coronavirus is a severe infectious disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that leads to increased mortality worldwide. It was first identified in Wuhan, China in December 2019. It initially started as an epidemic in China and eventually, the WHO declared this medical emergency as a global pandemic.1 Globally, as of 29 June 2020, there have been 10021401 confirmed cases of COVID-19 with 499913 deaths reported to WHO.2

A meta-analysis of 3062 patients positive for COVID-19 in China showed that the most common clinical manifestations are fever, fatigue, cough and expectoration. Other common symptoms included muscle soreness, anorexia, chest tightness and shortness of breath.3 It has also been reported that gastrointestinal symptoms are common in patients with COVID-19 infection.4

However, not much attention has been paid to pancreatic injury caused by COVID-19 infection. We report a case of COVID-19 who presented with severe acute necrotising pancreatitis (ANP) without any known risk factors.

CASE PRESENTATION

A 67-year-old Caucasian woman presented to our emergency department with a 1-day history of epigastric pain, diarrhoea and vomiting. Her significant surgical history consisted of laparotomy and a small bowel resection and anastomosis for a superior mesenteric artery (SMA) stenosis, a year back. She was on apixaban owing to her previous thrombotic event. Her only other comorbidity was well-controlled hypertension. On assessment in the emergency department, she was haemodynamically stable with a heart rate of 112 bpm, blood pressure of 158/90 mm Hg, and temperature of 37.5°C. Due to the nationwide lockdown that was in place at the time of presentation, she had ventured out of her house only for essential trips such as groceries and collection of medication. She was not in close contact with anyone known to have COVID-19. Her body mass index on the initial assessment was 27.5 kg/m². The patient reported having alcohol on just one or two occasions in a year and was a non-smoker. She was not known to have gallstones or diabetes. The patient is not on any hormone replacement therapy for postmenopausal symptoms.

DIFFERENTIAL DIAGNOSIS

On admission, a CT scan of the abdomen and pelvis with contrast was requested for diagnostic clarity. Her CT did not show any enhancement of the pancreatic head and body, indicating necrotising pancreatitis. It revealed extensive peripancreatic fluid collection (figure 1). The arterial blood gas analysis showed a partial pressure of oxygen (PO2) of 12 kPa on room air. An ultrasound scan of the abdomen did not detect any gallstones. Her serum amylase was significantly elevated at 1483 U/L. As it is not normal practice to analyse the serum lipase level in Kettering General Hospital (KGH) National Health Service Foundation Trust, we do not have a serum lipase value in her case. Her haemoglobin A1c level done during the course of her admission turned out to be within the normal range at 40 mmol/mol. Her other laboratory investigation results are listed in table 1.

Due to the patient’s worsening clinical status and her history of an SMA stenosis, a CT angiogram was done within the next 24 hours. This showed an interval progression of previously seen peripancreatic inflammatory changes and non-enhancement of most of the head and proximal body (necrotising pancreatitis) (figure 2).

INVESTIGATIONS

On admission, a CT scan of the abdomen and pelvis with contrast was requested for diagnostic clarity. Her CT did not show any enhancement of the pancreatic head and body, indicating necrotising pancreatitis. It revealed extensive peripancreatic fluid collection (figure 1). The arterial blood gas analysis showed a partial pressure of oxygen (PO2) of 12 kPa on room air. An ultrasound scan of the abdomen did not detect any gallstones. Her serum amylase was significantly elevated at 1483 U/L. As it is not normal practice to analyse the serum lipase level in Kettering General Hospital (KGH) National Health Service Foundation Trust, we do not have a serum lipase value in her case. Her haemoglobin A1c level done during the course of her admission turned out to be within the normal range at 40 mmol/mol. Her other laboratory investigation results are listed in table 1.

Due to the patient’s worsening clinical status and her history of an SMA stenosis, a CT angiogram was done within the next 24 hours. This showed an interval progression of previously seen peripancreatic inflammatory changes and non-enhancement of most of the head and proximal body (necrotising pancreatitis) (figure 2).
of pancreatitis and CT imaging confirmed a diagnosis of ANP, ruling out the above differential of small bowel obstruction.

The patient reported having a very limited alcohol intake and an ultrasound scan of the abdomen did not show any gallstones. It is acknowledged that gallstone-related acute pancreatitis can manifest without radiological evidence of gallstones if the gallstone has already passed or if the stones are too small to be detected by imaging. However, the lack of changes in the biliary tree and the normal Liver function test patterns do not suggest this as a possible explanation. This prompted us to look for other causes. Autoimmune pancreatitis was unlikely due to a normal immunoglobulin G4 (IgG4) level. The CT angiogram ruled out an ischaemic event and meanwhile, a reverse transcription PCR of her nasopharyngeal swab detected the presence of COVID-19 infection.

According to the revised Atlanta classification, the diagnosis of acute pancreatitis requires two of the following three features: (a) abdominal pain consistent with acute pancreatitis, (b) serum lipase activity (or amylase activity) at least three times greater than the upper limit of normal and (c) characteristic findings of acute pancreatitis on contrast-enhanced CT and, less commonly, MRI or transabdominal ultrasonography.

Thus, the clinical presentation of acute abdominal pain in the epigastric region, associated with an increased serum amylase level and CT imaging that demonstrated non-enhancement of the pancreatic parenchyma led us to our diagnosis of ANP.

TREATMENT

Following the results of the CT, fluid resuscitation was started immediately for a confirmed diagnosis of ANP. The patient was admitted in the acute surgical unit and was being managed conservatively with intravenous fluids and intravenous antibiotics.

The patient had to be moved to intensive care unit (ICU) as her vital signs deteriorated, particularly her respiratory rate which was high at 26 per minute. She had a new-onset oxygen requirement of 2 L to maintain a saturation of 96% (figure 3).

In ICU she was on an array of antibiotics including meropenem, metronidazole and clindamycin at various stages after

**Table 1** Laboratory investigation results

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>White cell count</td>
<td>18.1×10⁹/L</td>
</tr>
<tr>
<td>Platelet</td>
<td>502×10⁹/L</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>158 mg/L</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>0.4×10⁹/L</td>
</tr>
<tr>
<td>Amylase</td>
<td>1483 U/L</td>
</tr>
<tr>
<td>Creatinine</td>
<td>76 μmol/L</td>
</tr>
<tr>
<td>Urea</td>
<td>7.4 mmol/L</td>
</tr>
<tr>
<td>Estimated glomerular filtration rate</td>
<td>70.0 mL/min</td>
</tr>
<tr>
<td>Lactate</td>
<td>3.70 mmol/L</td>
</tr>
<tr>
<td>Procalcitom</td>
<td>1.22 μg/L</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>3.5 mmol/L</td>
</tr>
<tr>
<td>Calcium</td>
<td>2.24 mmol/L</td>
</tr>
<tr>
<td>IgG4</td>
<td>0.66</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>7 mg/dL</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>46 mg/dL</td>
</tr>
<tr>
<td>Alanine transaminase</td>
<td>22 mg/dL</td>
</tr>
<tr>
<td>Lactate dehydrogenase</td>
<td>213 U/L</td>
</tr>
<tr>
<td>SARS-CoV-2</td>
<td>Detected by reverse transcription PCR of nasopharyngeal swab at KGH Laboratory</td>
</tr>
<tr>
<td>Hepatitis B surface antigen</td>
<td>Negative</td>
</tr>
<tr>
<td>Hepatitis C antibody</td>
<td>Negative</td>
</tr>
<tr>
<td>Hepatitis A IgM</td>
<td>Negative</td>
</tr>
<tr>
<td>HbA1c (glycated haemoglobin)</td>
<td>40 mmol/mol</td>
</tr>
</tbody>
</table>

IgG4, immunoglobulin G4; IgM, immunoglobulin M; KGH, Kettering General Hospital.
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect

appropriate discussion with the clinical microbiologists. This antibiotic coverage was for the treatment of: necrotising pancreatitis, sepsis and COVID-19 pneumonia. She was not on any antiviral or anti-inflammatory medications nor on any medication that was a part of the COVID-19 RECOVERY Trial.6 The patient also did not require any form of ventilation or inotropic support during her stay in ICU.

OUTCOME AND FOLLOW-UP

Within 24 hours of admission, with her worsening clinical status, an urgent chest x-ray was requested. This showed bibasal linear atelectasis (figure 4). Subsequently, the patient’s COVID-19 swab that was done on admission returned back as positive. She was isolated immediately as per standard protocol.

The patient had severe inflammatory changes in the pancreas as shown by the CT accompanying her poor clinical status and coexisting COVID-19 infection. Therefore, she was moved to the ICU for close monitoring and management.

As her CT angiogram showed the progression of the peripancreatic and inflammatory changes, her case was discussed with the hepatobiliary surgeons in a nearby tertiary care centre who advised the continuation of conservative management. Following a 10-day stay in the ICU, the patient was stepped down to the ward and currently remains stable as an in-patient. A snapshot of the patient’s clinical parameters immediately after she was transferred to the ward is shown in figure 5. As of now, she is having physiotherapy to help regain her preadmission functional baseline. The overall management of the patient’s pancreatitis was not affected due to her COVID-19-positive status aside from having to be cared for in a COVID-19 ICU bay with appropriate personal protective equipment.

DISCUSSION

Several aetiological factors have been described for acute pancreatitis. The most common causes for acute pancreatitis are gallstones and heavy alcohol consumption.7 However, in 10%–20% of cases an aetiological factor cannot be identified.8 The patient denied excessive alcohol intake and an ultrasound scan did not show any evidence of gallstones.

A number of infectious agents, including viruses, parasites and bacteria are known to infect the pancreas.9 Viral pancreatitis has been extensively described in literature to be most commonly caused by mumps, Coxsackie B virus and hepatitis A virus.10 There were neither reasons for clinical suspicion, nor direct evidence of the above-mentioned viruses in our case. This increases the suspicion of COVID-19-induced pancreatitis. Coronavirus or coronavirus-like virus has been identified in pigeons with severe pancreatitis but no similar studies have been done in humans.11

A study of 52 patients with COVID-19 pneumonia showed that there was a 17% incidence of pancreatic injury. This study defined pancreatic injury as any abnormality in the serum amylase or lipase level.12 However, it is known that the pancreas is not the only source of the pancreatic enzymes (PE) amylase and lipase. For example, gastroenteritis is a well-recognised cause of raised PE. Furthermore, a meta-analysis of patients with COVID-19 showed that 18% had gastrointestinal symptoms.13 This indicates that raised PE in patients with COVID-19 cannot be directly attributed to pancreatitis.

In the previous global outbreak of severe acute respiratory syndrome (SARS) caused by SARS-associated coronavirus (SARS-CoV) in 2003, studies were done using immunohistochemistry and in situ hybridisation on autopsy samples of patients who died of SARS-CoV. These showed the presence of SARS-CoV antigen and RNA in pancreatic tissue.14 Genome sequences of SARS-CoV and SARS-CoV-2 are almost identical and share a 79.6% sequence identity.15 In a study that explored the expression and distribution of ACE2 receptor of SARS-CoV-2, it was reported that ACE2 is expressed more in the pancreas than the lungs.16 This potentiates the pancreas as a target for SARS-CoV-2. Although the exact pathogenesis of pancreatitis caused by COVID-19 is unclear,
it is thought to develop from the direct cytopathic effect mediated by the local replication of SARS-CoV-2.

The most serious complication of COVID-19 is sepsis-like inflammation leading to a dysregulated inflammatory response resulting in a cytokine storm. Excessive systemic inflammatory response syndrome in acute pancreatitis leads to distant organ damage and multiple organ dysfunction. Inflammatory mediators such as tumour necrosis factor-alpha, interleukin (IL)-6 and IL-10 play a critical role in the inflammatory response of both acute pancreatitis and COVID-19. Coexisting pancreatitis and COVID-19 lead to an accelerated clinical course and may be extremely challenging for the clinician to handle. In cases of ANP complicated by a secondary infection, interventions such as necrosectomies may be warranted. Such procedures pose as increased risks to the operating surgeon. This is due to the fact that SARS-CoV-2 is prevalent throughout the gastrointestinal tract and peritoneal fluid has a higher viral load than the upper respiratory secretions. The risk of exposure to healthcare workers is much higher in aerosol-generating procedures such as endoscopic or minimally invasive drainage/necrosectomy.

In conclusion, this report highlights the importance of the consideration of COVID-19 as a potential cause in patients presenting with idiopathic pancreatitis, especially during the pandemic. Operating surgeons and interventional radiologists who are involved in dealing with complications associated with pancreatitis need to be aware of the risk of infection.

**Learning points**

- Essential imaging, especially contrast-enhanced CT abdomen and pelvis, can be vital in patients with COVID-19 with abdominal pain.
- Adoption of a low threshold for escalation to intensive care unit is vital in patients presenting with acute pancreatitis and COVID-19.
- Donning of appropriate personal protective equipment is imperative for surgeons/interventionists dealing with potential complications of pancreatitis.
- An elevated serum amylase level in patients presenting with COVID-19 should not be directly attributed to pancreatitis without appropriate imaging to support the diagnosis.
- Further studies could be done to address how long the virus lasts in the peripancreatic fluid once the acute inflammatory episode is over.

**Twitter** Biraj K Karmakar @bkk_27

**Contributors** NKK was involved in the acquisition, analysis, interpretation of the data and drafting of the article. BKK revised the article for important intellectual content and gave final approval of the version published. NKK and BKK agree to be accountable for the article and to ensure that all questions regarding the accuracy or integrity of the article are investigated and resolved. OMT conceptualised the case report.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

**ORCID iDs**
Naren K Kumaran http://orcid.org/0000-0002-0706-9276
Ormond M Taylor http://orcid.org/0000-0003-4738-3283

**REFERENCES**